Posts tagged solid tumors
Chi-Med initiates fruquintinib clinical trial in U.S.

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.

Read More
Maxim vaults BeiGene price target to $120

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced solid tumors at the 20th annual meeting of the Chinese Society of Clinical Oncology in Xiamen, China.

Read More
Analysts starts Tocagen at buy, MP

Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5.

Read More
HCW ups Calithera price target to $14

H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on March 28.

Read More
Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21.

Read More
Ladenburg starts Leap Therapeutics at buy

Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.

Read More
Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Read More
Roth resumes coverage of Lion Biotech at buy

Roth Capital Partners has reinitiated coverage of Lion Biotechnologies (NASDAQ:LBIO) with a “buy” rating and $14 price target. The stock closed at $7.15 on Feb. 14.

Read More
HCW starts Calithera Biosciences at buy

H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5.

Read More
Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.

The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

Read More
Soricimed posts positive SOR-C13 data in solid tumors

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.

The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments.  SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.

Read More